Dabur gets approval for generic version of Camptosar in Italy & Denmark

Dabur Pharma Ltd has received approvals for irinotecan hydrochloride injection, generic version of Pfizer's Camptosar, in Italy and Denmark. The company had successfully launched the generic version of the drug in the US recently. It has also received approval for the drug in the UK.Ajay Kumar Vij, chief executive officer, Dabur Pharma Ltd., said, "We are extremely pleased to receive these approvals for irinotecan across Europe. This bear testimony to the strong foundation we are laying towards becoming one of the leading oncology players across the globe."Irinotecan hydrochloride injection is indicated as a component of first-line therapy in combination with 5-fluorouracil and leucovorin for patients with metastatic carcinoma of the colon or rectum. It is also indicated for patients with metastatic carcinoma of the colon or rectum where disease has recurred or progressed following initial fluorouracil based therapy.